---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-22-000016"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:16:46.580250+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q2 sales flat at $1.37B; lowers FY2022 outlook on FX, staffing

## Summary
- Q2 sales $1.37B flat YoY; underlying growth 5%. GAAP EPS $0.65, adjusted EPS $0.63.
- TAVR sales $907M (+1% reported, +5% underlying); TMTT $28M; Surgical $229M; Critical Care $211M.
- Full-year sales guidance lowered to $5.35-$5.55B; adjusted EPS guided to low end of $2.50-$2.65.
- Q2 share repurchases of $355M; Board approved new authorization with $1.9B remaining.
- Adjusted gross margin improved to 80.5% from 75.9%, helped by FX hedge gains.

## SEC filing metadata
- accession: 0001099800-22-000016
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/0001099800-22-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000016/ew-20220728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-22-000016
- JSON: https://secwatch.observer/filing/0001099800-22-000016.json
- Plain text: https://secwatch.observer/filing/0001099800-22-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.